Eric D. Jacobsen - Concepedia

Author

Eric D. Jacobsen

Also Known As

E D Jacobsen, E Jacobsen, E. D Jacobsen, E. D. Jacobsen, E. Jacobsen, E.D. Jacobsen, Eric D Jacobsen, Eric D. Jacobsen, Eric Jacobsen, Eric D. Jacobsen

357

Publications

18K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Washington University in St. Louis Massachusetts General Hospital

About

Eric D. Jacobsen is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	29	2.6K
2	Health Sciences	7	7	606
3	Public Health	3	3	167
4	Engineering	2	2	315
5	Natural Sciences	1	1	13

Eric D. Jacobsen

100

Publications

15.4K

Citations

H-Index

Page 1

	Year	Citations
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, New England Journal of Medicine	2017	5.7K
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, The Lancet	2018	707
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma John F. DiPersio, Ivana N. Micallef, Patrick J. Stiff, Journal of Clinical Oncology	2009	670
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown, Journal of Clinical Oncology	2011	630
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma Christopher J. Gibson, R. Coleman Lindsley, Vatche Tchekmedyian, Journal of Clinical Oncology	2017	455
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial Michael Wang, Simon Rule, Pier Luigi Zinzani, The Lancet Lymphoid NeoplasiaOncologyPathologyPhase 2Medicine	2017	428
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma Oreofe O. Odejide, Oliver Weigert, Andrew A. Lane, Blood	2013	423
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin Steven M. Horwitz, Ranjana H. Advani, Nancy L. Bartlett, Blood	2014	349
2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Mark W. Clemens, Eric D. Jacobsen, Steven M. Horwitz Aesthetic Surgery Journal Surgical OncologyBreast OncologyCancer ManagementCancer RegistrationSurgery	2019	317
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice Elizabeth C. Townsend, Mark A. Murakami, Alexandra Christodoulou, Cancer Cell Knockout MouseXenotransplantationXenografts Enables DiscoveryEngineeringIn Vivo System	2016	302

Page 1